US Biomarkers, Inc. is a privately held, molecular diagnostics company and provider of epigenetic biomarker products and services with a focus on clinical assays and companion diagnostics for cancer and neurodegenerative diseases.US Biomarkers a unique leadership position in genomewide analysis of D…
US Biomarkers, Inc. is a privately held, molecular diagnostics company and provider of epigenetic biomarker products and services with a focus on clinical assays and companion diagnostics for cancer and neurodegenerative diseases.
US Biomarkers a unique leadership position in genomewide analysis of DNA methylation in ultra small samples and development of signature biomarkers for cancer and neurodegenerative diseases. Our proprietary MethDet technology provides an unmatched potential to become a worldwide leader in Molecular Medicine by developing clinical biomarkers and clinical tests for differential diagnosis, personalized medicine, companion diagnostics, prognosis and monitoring.
Our unmatched technology brings a unified platform to diagnostic testing in an inexpensive and yet comprehensive format. In one test we will determine the presence of multiple diseases, their nature and location. Our commercial partners will benefit from companion diagnostic tests to accurately target their new drugs and weed out unpromising candidates early.
Team (1)
Sectors US Biomarkets, Inc. serves:
Health Care
Join Axial's Private M&A Platform
US Biomarkets, Inc. connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
